Physician profile
Brian D Wernick
NPI 1629418975
$5,879.63
in general payments reported to CMS, 2019-2025
14 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,315 · 2020: $1,059 · 2022: $2,032 · 2023: $195 · 2024: $32.93 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $4,172.29 | 2019-2024 | Gore Excluder Iliac Branch Endoprosthesis |
| Cook Medical LLC | $715.03 | 2019-2020 | |
| Medtronic Vascular, INC. | $449.17 | 2019-2020 | |
| Shockwave Medical, INC | $193.77 | 2025 | |
| Acera Surgical, INC. | $103.60 | 2023 | Restrata Wound Matrix |
| Medtronic, INC. | $93.17 | 2022-2025 | Heli-Fx Endoanchor System, Closurefast |
| Mozarc Medical US LLC | $34.71 | 2023 | Argyle |
| Integra Lifesciences Corporation | $21.01 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Lemaitre Vascular, INC. | $20.64 | 2025 | Hydro Lemaitre Valvulotome |
| Abbott Laboratories | $18.38 | 2023 | Allure Quadra |
| Solventum Corporation | $17.38 | 2024 | Prevena |
| Bard Peripheral Vascular, INC. | $14.02 | 2022 | |
| Pfizer INC. | $13.47 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.